Lion TCR, a Singapore-headquartered clinical-stage biotech company, saw its losses widen by 27% in 2023 from a year earlier as it continues to operate on zero revenues, regulatory filings showed.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
